InterCure is reviewing US medical cannabis opportunities after federal rescheduling moved certain state-licensed medical cannabis from Schedule I to Schedule III. The company says the regulatory change prompted a focused evaluation of regulated U.S. medical markets and how InterCure’s recent acquisition expands its commercial options.
InterCure completed the initial closing of its acquisition of Botanico Ltd. (also known as ISHI). As part of that first tranche the company issued 2,471,061 ordinary shares and said it will issue an additional 2,470,073 shares when conditions in the share purchase agreement are met. Combined, the two tranches total 4,941,134 ordinary shares tied to the transaction.
Under the deal, InterCure secures exclusive rights to a portfolio of U.S. genetics and branded assets. The acquisition gives the company access to award-winning American cannabis genetics, proprietary strains, premium brands and production technologies developed by Botanico/ISHI.
Botanico’s technical capabilities are central to InterCure’s stated plans. The company acquires AI-driven cultivation tools, automated production systems and strategic brand alliances with U.S. operators, including The Flowery. InterCure said those assets aim to accelerate product development and scale manufacturing within regulated markets.
InterCure reported its first meaningful revenues from Germany earlier this year, which the company cites as proof of early commercial traction in a large European medical market. To support sales in Germany, InterCure has hired a local management and sales team and plans multiple product launches in the second half of the year.
InterCure’s U.S. review is limited to regulated medical cannabis markets. The company stated it is not evaluating recreational or unregulated channels. Executives say the review will consider ways to deploy Botanico’s genetics, brands and production technologies within the constraints of U.S. state and federal rules.
CEO and chairman Alexander Rabinovitch said: “The Botanico acquisition, German market momentum and evolving U.S. regulatory landscape support the company’s vision of building a leading international medical cannabis company serving patients across multiple regulated markets.” He added that the firm will prioritize markets and partners where compliance, supply chain controls and clinical-grade production standards align with InterCure’s pharmaceutical-focused strategy.
Key, quantifiable elements of the transaction and strategy: – Shares issued at initial closing: 2,471,061 ordinary shares. – Additional shares contingent on closing conditions: 2,470,073 ordinary shares. – Total shares associated with the transaction if all conditions are met: 4,941,134 ordinary shares. – Primary immediate commercial market with reported revenues: Germany. – Planned product rollout: multiple launches anticipated in Germany in H2 of the year.
InterCure emphasized that the Botanico portfolio includes specific U.S. genetics and branded formulations that can be reproduced under controlled production systems. The company highlighted AI-driven cultivation controls and automated production lines as tools to maintain batch consistency, measure potency, and reduce human error in cultivation and processing.
The federal rescheduling cited by InterCure represents a material change for companies that hold or seek cross-border assets. Rescheduling from Schedule I to Schedule III reduces certain federal restrictions on research, banking access and interstate commerce for federally recognized products, while state regulatory regimes continue to control licensing, labeling and distribution. InterCure’s public statement framed the change as a factor that opens new, regulated pathways worth evaluating.
InterCure’s announcement did not disclose detailed financial terms beyond the share issuances, nor did it specify timelines for potential U.S. market entries. The company said it will report further developments as the strategic review progresses and as closing conditions for the remaining shares are satisfied.
For investors and market observers, the transaction links an Israeli-listed medical cannabis firm with U.S. genetics and branded assets at a time when federal policy around medical cannabis is changing. InterCure’s next public milestones will include updates on the Botanico integration, the issuance of the contingent shares, and the company’s decisions about which U.S. state markets to enter under regulated medical frameworks.
